These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8347601)

  • 1. Inhibition of human immunodeficiency virus-1 protease by a C2-symmetric phosphinate. Synthesis and crystallographic analysis.
    Abdel-Meguid SS; Zhao B; Murthy KH; Winborne E; Choi JK; DesJarlais RL; Minnich MD; Culp JS; Debouck C; Tomaszek TA
    Biochemistry; 1993 Aug; 32(31):7972-80. PubMed ID: 8347601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystallographic analysis of transition-state mimics bound to penicillopepsin: phosphorus-containing peptide analogues.
    Fraser ME; Strynadka NC; Bartlett PA; Hanson JE; James MN
    Biochemistry; 1992 Jun; 31(22):5201-14. PubMed ID: 1606144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational design, synthesis, and crystallographic analysis of a hydroxyethylene-based HIV-1 protease inhibitor containing a heterocyclic P1'--P2' amide bond isostere.
    Thompson SK; Murthy KH; Zhao B; Winborne E; Green DW; Fisher SM; DesJarlais RL; Tomaszek TA; Meek TD; Gleason JG
    J Med Chem; 1994 Sep; 37(19):3100-7. PubMed ID: 7932533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A check on rational drug design: crystal structure of a complex of human immunodeficiency virus type 1 protease with a novel gamma-turn mimetic inhibitor.
    Hoog SS; Zhao B; Winborne E; Fisher S; Green DW; DesJarlais RL; Newlander KA; Callahan JF; Moore ML; Huffman WF
    J Med Chem; 1995 Aug; 38(17):3246-52. PubMed ID: 7650677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure of HOE/BAY 793 complexed to human immunodeficiency virus (HIV-1) protease in two different crystal forms--structure/function relationship and influence of crystal packing.
    Lange-Savage G; Berchtold H; Liesum A; Budt KH; Peyman A; Knolle J; Sedlacek J; Fabry M; Hilgenfeld R
    Eur J Biochem; 1997 Sep; 248(2):313-22. PubMed ID: 9346283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. X-ray crystallographic studies of a series of penicillin-derived asymmetric inhibitors of HIV-1 protease.
    Jhoti H; Singh OM; Weir MP; Cooke R; Murray-Rust P; Wonacott A
    Biochemistry; 1994 Jul; 33(28):8417-27. PubMed ID: 8031777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystal structure of a complex of HIV-1 protease with a dihydroxyethylene-containing inhibitor: comparisons with molecular modeling.
    Thanki N; Rao JK; Foundling SI; Howe WJ; Moon JB; Hui JO; Tomasselli AG; Heinrikson RL; Thaisrivongs S; Wlodawer A
    Protein Sci; 1992 Aug; 1(8):1061-72. PubMed ID: 1304383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Free energy perturbation studies on binding of A-74704 and its diester analog to HIV-1 protease.
    Rao BG; Murcko MA
    Protein Eng; 1996 Sep; 9(9):767-71. PubMed ID: 8888142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-dimensional structure of a simian immunodeficiency virus protease/inhibitor complex. Implications for the design of human immunodeficiency virus type 1 and 2 protease inhibitors.
    Zhao B; Winborne E; Minnich MD; Culp JS; Debouck C; Abdel-Meguid SS
    Biochemistry; 1993 Dec; 32(48):13054-60. PubMed ID: 8241159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate -- interactions with frequently occurring glutamic acid residue at P2' position of substrates.
    Weber IT; Wu J; Adomat J; Harrison RW; Kimmel AR; Wondrak EM; Louis JM
    Eur J Biochem; 1997 Oct; 249(2):523-30. PubMed ID: 9370363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of the X-ray structures of HIV-1 and HIV-2 proteases in complex with CGP 53820, a novel pseudosymmetric inhibitor.
    Priestle JP; Fässler A; Rösel J; Tintelnot-Blomley M; Strop P; Grütter MG
    Structure; 1995 Apr; 3(4):381-9. PubMed ID: 7613867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based design of symmetric inhibitors of HIV-1 protease.
    Erickson J; Kempf D
    Arch Virol Suppl; 1994; 9():19-29. PubMed ID: 8032250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease.
    Erickson J; Neidhart DJ; VanDrie J; Kempf DJ; Wang XC; Norbeck DW; Plattner JJ; Rittenhouse JW; Turon M; Wideburg N
    Science; 1990 Aug; 249(4968):527-33. PubMed ID: 2200122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The crystal structures at 2.2-A resolution of hydroxyethylene-based inhibitors bound to human immunodeficiency virus type 1 protease show that the inhibitors are present in two distinct orientations.
    Murthy KH; Winborne EL; Minnich MD; Culp JS; Debouck C
    J Biol Chem; 1992 Nov; 267(32):22770-8. PubMed ID: 1429626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A symmetric inhibitor binds HIV-1 protease asymmetrically.
    Dreyer GB; Boehm JC; Chenera B; DesJarlais RL; Hassell AM; Meek TD; Tomaszek TA; Lewis M
    Biochemistry; 1993 Jan; 32(3):937-47. PubMed ID: 8422397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystal structure of human immunodeficiency virus (HIV) type 2 protease in complex with a reduced amide inhibitor and comparison with HIV-1 protease structures.
    Tong L; Pav S; Pargellis C; Dô F; Lamarre D; Anderson PC
    Proc Natl Acad Sci U S A; 1993 Sep; 90(18):8387-91. PubMed ID: 8378311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance.
    Hong L; Zhang XC; Hartsuck JA; Tang J
    Protein Sci; 2000 Oct; 9(10):1898-904. PubMed ID: 11106162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy.
    Lindberg J; Pyring D; Löwgren S; Rosenquist A; Zuccarello G; Kvarnström I; Zhang H; Vrang L; Classon B; Hallberg A; Samuelsson B; Unge T
    Eur J Biochem; 2004 Nov; 271(22):4594-602. PubMed ID: 15560801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition and catalytic mechanism of HIV-1 aspartic protease.
    Silva AM; Cachau RE; Sham HL; Erickson JW
    J Mol Biol; 1996 Jan; 255(2):321-46. PubMed ID: 8551523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Energy calculations and analysis of HIV-1 protease-inhibitor crystal structures.
    Gustchina A; Sansom C; Prevost M; Richelle J; Wodak SY; Wlodawer A; Weber IT
    Protein Eng; 1994 Mar; 7(3):309-17. PubMed ID: 8177879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.